Phaseline

Targets › ABCA1

ABCA1 (Phospholipid-transporting ATPase ABCA1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 4, 1 Phase 2; Neurology, Metabolic and endocrine; next expected readout Apr 2027.

Catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of membrane coupled to the hydrolysis of ATP. Thereby, participates in phospholipid transfer to apolipoproteins to form nascent high density lipoproteins/HDLs. Transports preferentially phosphatidylcholine over phosphatidylserine. (UniProt, O95477)

Open in Phaseline: the race on ABCA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
General Hospital of Shenyang Military RegionProbucol
ATP-binding cassette sub-family A member 1 inhibitor
ABCA1Phase 4Stroke, IschemicNov 2027
First Affiliated Hospital of Wannan Medical CollegeProbucol
ATP-binding cassette sub-family A member 1 inhibitor
ABCA1Phase 3Ischemic StrokeApr 2028
River 3 RenalR3R01
ATP-binding cassette transporter A1 (ABCA1) inducer that increases efflux of cholesterol f
ABCA1Phase 2Diabetic Kidney DiseaseApr 2027

Conditions

Ischemic Stroke (1) Stroke, Ischemic (1) Diabetic Kidney Disease (1)

Modalities

small molecule (3)

Companies

First Affiliated Hospital of Wannan Medical College (1) General Hospital of Shenyang Military Region (1) River 3 Renal (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.